Skip to content
OpenCapital
Get started

Solid Biosciences Inc. SLDB Internal Research And Development Expense — Research And Development Expense

Other product segments

SGT003
$22.94M+150%
External General And Administrative Expense
$19.47M-3.2%
SGT501
$1.41M-68.5%

Similar metrics at other companies

Disc Medicine logo
IRONInternal Research And Development — Research And Development Expense
$11.31M+67.6%
Nurix Therapeutics, Inc. logo
NRIXInternal research and development expenses — R&D
$57.07M+12.2%
Innoviva, Inc. logo
INVAInternal Expenses — Research And Development Expense
$2.64M+95.9%
BioCryst Pharmaceuticals logo
BCRXResearch, discovery and preclinical programs — Research and Development Expense (Excluding Acquired in Process Cost)
$3.97M+30.4%
MapLight Therapeutics, Inc. logo
MPLTEmployee Related — Research And Development Expense
$15.99M+127%
Scholar Rock logo
SRRKEarly Research — Research And Development Expense
$1.21M-16.8%

Other financials

Income statement

See full
Revenue$2.0M-40.6%
Operating income-$57.3M-43.1%
Net income-$56.7M-44.4%
EPS (diluted)-$0.52+11.9%

Balance sheet

See full
Cash & equivalents$297.1M+41.1%
Total debt$20.7M-12.5%
Total equity$374.1M+27.1%
Total assets$422.9M+23.0%

Cash flow

See full
Operating cash flow-$47.2M-48.3%
CapEx$165.0K+31.0%
Free cash flow-$47.4M-48.2%

Valuation

See full
Market cap$910.66M+145%
Enterprise value$634.23M+244%
P/S112.5×-10.3×

Profitability

See full
Operating margin-1,315.2%-4,060pp
Net margin-1,062.3%-251,151pp
FCF margin-1,247.7%-9,569pp

Returns & leverage

See full
Return on equity-57.4%+2.2pp
Debt / equity0.1×0.0×
Current ratio13.1×+2.2×

Where this comes from

Reported directly by Solid Biosciences Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Solid Biosciences Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Solid Biosciences Inc.'s internal research and development expense — research and development expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Solid Biosciences Inc.'s internal research and development expense — research and development expense?
Solid Biosciences Inc. (SLDB) reported internal research and development expense — research and development expense of $9.15M in Q1 2026.
How has Solid Biosciences Inc.'s internal research and development expense — research and development expense changed year-over-year?
Solid Biosciences Inc.'s internal research and development expense — research and development expense increased by 33.7% year-over-year, from $6.84M to $9.15M.
What is the long-term trend for Solid Biosciences Inc.'s internal research and development expense — research and development expense?
Over 2 years (2023 to 2025), Solid Biosciences Inc.'s internal research and development expense — research and development expense has grown at a 16.0% compound annual growth rate (CAGR), from $21.8M to $29.34M.
What does internal research and development expense — research and development expense mean?
This metric represents the total operating costs directly attributable to the internal research and development activities for specific therapeutic programs or product candidates. It captures the investment in scientific discovery, preclinical studies, and clinical trial execution required to advance the company's pipeline toward regulatory approval. Monitoring this expense provides insight into the company's commitment to innovation and the capital intensity required to sustain its drug development lifecycle.